Applicant: William Thomas Melvin et al. Attorney's Docket No.: 12489-003002 / UMMC 96-01

Serial No.: 09/874,166 Filed: June 4, 2001

Page : 2 of 8

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1-26. (Canceled)

- 27. (Currently Amended) A method for stimulating the human immune system activating T cells in a subject, the method comprising administering to the subject an amount of a cytochrome P450 CYP1B1 sequence effective to activate activating human T cells that recognize a human CYP1B1 epitope.
- 28. (Previously Presented) The method of claim 27, wherein activation of T cells is achieved by immunizing a human with a CYP1B1 amino acid sequence.
- 29. (Currently Amended) The method of claim 28, wherein the method comprises immunizing the human with the CYP1B1 amino acid sequence activates activates activating cytotoxic T cells.
- 30. (Currently Amended) The method of claim 28, wherein the method comprises immunizing the human with the CYP1B1 amino acid sequence activates activating helper T cells.
 - 31. (Previously Presented) The method of claim 28, wherein the human has a cancer.

Applicant: William Thomas Melvin et al. Attorney's Docket No.: 12489-003002 / UMMC 96-01

Serial No.: 09/874,166, Filed: June 4, 2001 Page: 3 of 8

32. (Previously Presented) The method of claim 31, wherein the cancer is in the bladder, brain, breast, colon, connective tissue, kidney, lung, lymph node, esophagus, ovary, skin, stomach, testis, or uterus.

- 33. (Previously Presented) The method of claim 31, wherein the immunization results in a cell-mediated or humoral immune response against the cancer.
- 34. (Previously Presented) The method of claim 28, wherein the CYP1B1 amino acid sequence comprises ESLRPGAAPRDMMD (SEQ ID NO:1).
- 35. (Previously Presented) The method of claim 28, wherein the CYP1B1 amino acid sequence comprises EKKAAGDSHGGGAR (SEQ ID NO:2).

36-40. (Canceled)